Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
CATALYST PHARMACEUTICALS, INC. (CPRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
08/25/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update"
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/28/2023 8-K Quarterly results
07/21/2023 8-K Quarterly results
07/17/2023 ARS Form ARS - Annual Report to Security Holders:
07/12/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
06/01/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023"
05/30/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K",
"Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors"
05/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year"
05/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE ® From 80 mg Per Day To 100 mg Per Day"
04/24/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
03/31/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/15/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update"
03/15/2023 10-K Annual Report for the period ended December 31, 2022
03/07/2023 8-K Other Events  Interactive Data
02/14/2023 SC 13G/A ARMISTICE CAPITAL, LLC reports a 0% stake in CATALYST PHARMACEUTICALS, INC.
02/10/2023 SC 13G/A Flynn James E reports a 5.6% stake in Catalyst Pharmaceuticals, Inc.
02/08/2023 SC 13G/A STATE STREET CORP reports a 7.6% stake in AMEMDED FILING CATALYST PHARMACEUTICALS INC
02/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance"
01/30/2023 8-K Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits  Interact...
Docs: "FORM 8-K",
"Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® CIII"
01/26/2023 SC 13G/A BlackRock Inc. reports a 15.1% stake in CATALYST PHARMACEUTICALS INC
01/24/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11 th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra Announced Earlier Today-Notice Received from ANDA Filer for FIRDAPSE ®"
01/23/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE ®"
01/20/2023 SC 13G/A BlackRock Inc. reports a 15.1% stake in CATALYST PHARMACEUTICALS INC
12/22/2022 8-K Acquisition/merger/asset purchase announced
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Asset Purchase Agreement by and between Eisai and the Company, (certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed)",
"Form of Transition Services Agreement between Eisai, Inc., a subsidiary of Eisai, and the Company (certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed)",
"Form of Supply Agreement between Eisai and the Company (certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed)",
"Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA ® CIII From Eisai Co., Ltd"
11/14/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
11/09/2022 8-K Quarterly results
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/07/2022 SC 13G/A BlackRock Inc. reports a 14.9% stake in CATALYST PHARMACEUTICALS INC
09/29/2022 8-K Quarterly results
09/19/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
09/09/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment No. 8 to Employment Agreement between the Company and Patrick J. McEnany",
"Amendment No. 8 to Employment Agreement between the Company and Patrick J. McEnany"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy